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ABSTRACT
Intracranial Hypertension is a neurological condition secondary to raised intracranial pressure in the absence of 
identifiable intracranial pathology and with normal cerebrospinal fluid composition. It can be a challenging condition to 
manage. One of the treatment modalities, optic nerve sheath fenestration is an important, yet under utilized mode of 
treatment, particularly in patients with visual symptoms.
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C O M M E N T R Y
INTRODUCTION:
Intracranial Hypertension (IIH) is a neurological disorder 
characterized by raised cerebrospinal fluid pressure 
without identifiable intracranial pathology and with 
normal cerebrospinal fluid (CSF) composition.1 This 
condition usually affects overweight women of 
childbearing age but can affect either gender at any 
age. The incidence is 0.9-2.2 per 100,000 in the 
general population rising to 19.3-21.3 per 100,000 in 
obese women of childbearing age.1
PATHOGENESIS:
The pathogenesis is unclear. Various factors including 
obesity, sex hormone, prothombotic factors and altered 
CSF dynamics have been suggested for the same.2
Obesity has long been associated with IIH. In a 
prospective study of 34 patients with IIH, Rowe3 
showed 94% of their patients to be overweight (BMI 
>26kg/m2) and 73% obese (BMI >30 kg/m2). Obese 
females between the ages 16-24 were 17 times more 
likely to develop IIH than their age-matched controls.3
PRESENTATION: 
Patients with IIH can present with visual and non-visual 
symptoms. In a prospective study of 50 patients, Wall 
and George4 reported headache in 94% of their 
patients, transient visual obscurations in 68%, 
intracranial noise in 58%, photopsia in 54% and 
retrobulbar pain in 44% of patients.  Papilledema is 
considered to be the cardinal sign of IIH. In the absence 
of papilledema, obesity and pulsatile tinnitus can 
suggest high CSF pressure in a patient with chronic 
headaches. Wall and George4 also reported impairment 
of visual acuity in 13% of their patients’ initial visits and 
of visual field abnormality in 90% of their patients on 
perimetry. Typical visual field defects were blind spot 
enlargement, nasal defect, arcuate scotoma and 
generalized field constriction.
Friedman5 described an updated criterion for 
diagnosing IIH (Table 1). The diagnosis of IIH requires 
presence of papilledema (Table 2 and 3), appropriate 
brain imaging to exclude intracranial abnormalities and 
a lumbar puncture to document raised intracranial 
pressure (>25cm H2O) and normal CSF constituents.
5 
Magnetic resonance imaging (MRI) is considered better 
than a computed tomography (CT) scan, however, in 
atypical cases magnetic resonance venography (MRV) 
along with MRI may be required. MRI may reveal signs 
of empty sella turcica, flattening of posterior globe and 
buckling of optic nerve. Ventricular size should be 
normal for the patient’s age, however slit-like ventricle 
may be seen in IIH.6
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IIH is a diagnosis of exclusion and conditions mimicking 
IIH should be excluded (Table 4). Various conditions are 
associated with IIH and need to be considered in the 
workup of the patient (Table 5)7. Bababeyge described 
two non-obese patients on minocycline who developed 
visual loss secondary to papilledema.8
Table 1. Modified Criteria for Diagnosis IIH [Friedman & 
Jacobson]
Table 2: Feature of papilledema 
Table 3: Grading of papilledema 
 
Table 4: Differential Diagnosis
Table 5: List of systemic diseases and medications 
associated with intracranial hypertension
TREATMENT: 
Treatment of IIH includes weight reduction, medical 
management, elimination of associated factors, serial 
lumbar puncture and surgical intervention
NON-SURGICAL TREATMENT
Johnson9 observed that at least 6% of weight loss could 
result in reduction of ICP with accompanying resolution 
of papilledema and visual field dysfunction.  Surgically 
induced weight loss has shown similar results.7
The mainstay of IIH medical management is 
acetazolamide, a carbonic anhydrase inhibitor that 
reduces CSF production by decreasing sodium ion 
transport across the choroidal epithelium. The starting 
dose is 250 mg twice daily to ensure tolerance, 
increasing to a maintenance dose of 1-2 g per day. 
Patients intolerant to acetazolamide can be treated 
with furosemide (loop diuretic) an ACE inhibitor or 
topiramate an anti-convulsion drug. IIH symptoms may 
resolve after lumbar puncture.7
SURGICAL TREATMENT
The surgical options are optic nerve sheath fenestration 
(ONSF) or CSF diversion procedures such as 
lumboperitoneal shunt (LPS) or ventriculoperitoneal 
shunts (VPS).
Optic nerve sheath fenestration (ONSF) was first 
described by DeWecker 10 to allow the flow of CSF from 
Criteria for diagnosing idiopathic intracranial hypertension
• Symptoms, if present, are only those of generalized intracranial hypertension or 
papilledema  
• Signs, if present, are only those of generalized intracranial hypertension or 
papilledema  
• Elevated CSF pressure demonstrated on lumbar puncture in the lateral 
decubitus position  
• Normal CSF constituents  
• No evidence of space occupying lesion or venous sinus thrombosis on imaging  
• No other explanation for the raised CSF pressure
Features of papilledema
• Peripapillary nerve fiber layer edema obscuring the retinal blood vessels  
• Absent spontaneous venous pulsations  
• Distended retinal veins  
• Peripapillary haemorrhages and exudates  
• Peripapillary retinal or choroidal folds  
• Nerve fiber layer infarcts
Stage Description
0 Normal optic disc. Radial nerve fiber layers without nerve fiber 
layertortuosity. Blurring of nasal, superior, inferior margins 
inversely proportional to disc size. Greater the size, less the 
blurring. 
1 C-shaped halo. Normal temporal margin. Concentric or radial 
retrochoroidal folds. 
2 Circumferential halo. Nasal border elevation. 
3 Obscuration of one or more segment of a major blood vessel. 
4 Total obscuration on the disc of a segment of a major blood 
vessel. Elevation of the entire nerve head, including the cup. 
5 Partial obscuration of all the blood vessels on the optic disc and 
total obscuration of at least one major blood vessel. Dome shape 
protrusion, representing anterior expansion of the optic nerve 
head.  
Important differential diagnosis of Idiopathic intracranial hypertension
Dural venous sinus thrombosis 
Hypertensive retinopathy 
Optic disc anomalies (disc drusen and tilted optic disc) 
Intracranial hypertension due to medication or a disease 
Systemic diseases and medications associated with intracranial 
hypertension
  esaesid cimetsyS noitacideM
Tetracycline 
Minocycline 
Doxycycline 
Steroids 
Steroid withdrawal 
Vitamin A 
Systemic Lupus Erythematosis 
Behcet’s disease 
Polycystic ovarian disease 
Hypothyroidism 
the sub-arachnoid space to the orbital space.  Almost a 
century later, in 1964, Hayreh 11 refined the technique 
of ONSF that resulted in the resolution of papilledema. 
This led to the theory that ONSF could be the preferred 
surgical option when headache is not the predominant 
symptom.12 CSF shunting is considered to be the 
procedure of choice when headache is the 
predominant symptom.13 However, studies have shown 
significant reduction of the symptoms of headache 
after ONSF, which may suggest the role of ONSF as an 
alternative, for patients with headaches as the 
predominant symptom.14
Banta and Ferris 15 described the effectiveness of ONSF 
in a case series involving 158 eyes by demonstrating 
improvement in the visual acuity of 94% of the eyes 
post surgery. In addition, 88% showed stabilization or 
improvement in the visual field. One eye suffered 
visually significant complication. The study reported 
less favorable outcome for the symptoms of headache. 
In this study, 61 patients presented with headache and 
only 31% reported improvement in their headache post 
ONSF. 
A study by Chandrasekaran et al16, on 51 eyes of 32 
patients demonstrated that patients with mild visual 
field defect improved or stabilized post ONSF, while 
patients with severe visual field defect were found to 
stabilize post ONSF. Also younger patients showed 
more favorable result in this study. In the study it was 
found overall complication rate of 15.6%; all being 
self-limiting, three patients had diplopia, two had 
anisocoria and one had disc hemorrhage. All 
procedures were approached by medial subconjunctival 
approach and performed by the same surgeon. Plotnik 
and Kosmorsky17 reported a complication rate of 40%, 
which included temporary motility disorder (29%), 
pupillary dysfunction (11%) and vascular complication 
(11%): comprising of two central retinal artery 
occlusion, one transient outer retinal ischemia and one 
superotemporal branch retinal artery occlusion. 
Sergott18 studied the benefit of ONSF in patients with 
prior LPS placement. The study enrolled 23 patients 
with previous multiple LPS; visual improvement was 
demonstrated in six patients after ONSF. This suggested 
that despite functional CSF shunt, ONSF could be 
beneficial in patients with progressive visual 
deterioration, or in the event of failure of the shunt. 
In a retrospective review of 62 eyes by Alsuhaibani et 
al19 found an additional benefit of unilateral ONSF to 
reduce the disc swelling in the contralateral 
un-operated eye. The reduced disc swelling in the 
contralateral eye continued improving with greatest 
effect seen 12 months post ONSF, corresponding with 
improvement in the visual function. 
In general, ONSF is an effective long‐term procedure for 
visual loss associated with IIH. Multiple studies have 
reported that majority of complication are often 
transient and resolve without long-term effects. 
ONSF is considered to be the better option in patients 
with visual loss in IIH, while CSF shunting is the 
favorable option in patients with refractory headache. 
The two commonly performed CSF shunting 
procedures, ventricular peritoneal shunt (VPS) and 
Lumboperitoneal shunt (LPS), are considered to be 
almost similar in their outcome. Tarnaris et al20, in a 
retrospective review of 34 patients with 63 shunts 
found no significant difference in visual outcome or 
headache between the two groups; VPS and LPS, 
however, headache improved more than visual 
disturbance for both the groups. The study also 
reported 20.5% of the patients had shunt procedure 
related complication with 35% requiring shunt revision. 
Abubaker 12 similarly found better outcomes with 
headache compared to visual disturbance post CSF 
shunting procedure and also noted LPS to have lower 
failure rate but higher revision rate. El-Saadany21, in the 
retrospective review of 22 patients, found patients 
showed improvement in both headache (19/22) and 
papilledema (16/22). Moreover, the study reported 9% 
shunt infection rate, 27% shunt obstruction and 13% 
shunt over drainage. A 10-year retrospective review of 
53 patients by Sinclair 22 found an overall improvement 
in the visual symptoms post-shunting but noted 
headache persisted in 79% of post-LPS patients. The 
review also noted a high rate of shunt complications, 
shunt revisions, and persistent post-shunt headache. 
Karabatsou23 et al retrospectively reviewed 21 post LPS 
patients. The study highlighted7 shunt related 
infections, 7 tonsillar herniations, 17 shunt migrations 
with 18 out of 22 patients requiring a total of 63 shunt 
revision procedures. 
SURGICAL TECHNIQUE OF ONSF
Although many techniques have been described in 
literature, the preferred method for the author is lid 
crease approach. Other commonly used methods for 
access to the nerve are via medial orbitotomy and 
lateral orbitotomy. 
Medial orbitotomy involves an approach to the optic 
nerve without cutting the skin. The medial rectus is 
detached and the optic nerve is identified. Once in view, 
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the optic nerve sheath is fenestrated to release the 
fluid. There is a risk of ocular muscle palsy with this 
surgery. Lateral orbitotomy approach involves skin 
incision, removal of the lateral orbital wall, giving a wide 
access to the optic nerve. However, it is a longer 
surgical procedure with a possible risk of damage to the 
ciliary body. The lid crease approach is gaining favor, as 
it does not involve bone removal or muscle detachment 
but the learning curve is considerably higher in this 
approach.13
SOCIETAL IMPACT OF IDIOPATHIC INTRACRANIAL 
HYPERTENSION:
The societal impact of this condition is high and often 
goes unrecognized. According to the intracranial 
hypertension registry in the USA, in 2007 the total cost 
of IIH was estimated to be 444 million USD, of which 
232 million USD is attributable to direct medical and 
surgical expense.24
CONCLUSION
IIH can cause visual loss. Medical management is the 
first line of treatment in IIH. In refractory cases and in 
patients presenting with visual loss, optic nerve sheath 
fenestration is an important and viable treatment 
option to prevent sight loss in this challenging 
neuro-ophthalmological condition. 
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